Notably, Kaplan-Meier survival curves and log-rank tests revealed that patients with high MYBL2 expression had significantly poorer disease-free survival (DFS) than those with low MYBL2 expression (P = 0.003; Figure 1G), which was consistent with the results from the TCGA PRAD cohort (Figure S1G). Here, MYBL2 is linked to prostate adenocarcinoma.